Search results: Sage Journals

Restricted accessResearch articleFirst published 2026

Validation of Manual In-House Synthesis,Imaging,Biodistribution,and Dosimetry of Tb-161 PSMA-617 for mCRPC Patients in a Tertiary Health Care Center: A Proof-of-Concept Study

Parul Thakral, Nishant Rana, Abhishek Uppal [...]

Cancer Biotherapy and Radiopharmaceuticals

Open accessReview articleFirst published 2022

Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review

Isabel Heidegger, Claudia Kesch, Alexander Kretschmer [...]

Therapeutic Advances in Medical Oncology

Open accessCase reportFirst published 2023

Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review

Duncan E. K. Sutherland, Raghava Kashyap, Price Jackson [...]

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published April, 2025

Intratumoral Distribution of [ 177 Lu]Lu-PSMA-617 Over Time and in Relation to Diagnostic Tracers in Animal Models of Prostate Cancer

Anders Örbom, Joanna Strand, Mohamed Altai [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published October, 2021

Therapeutic Multidose Preparation of a Ready-to-Use 177 Lu-PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy

Avik Chakraborty, Arpit Mitra, Megha Tawate [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published October, 2016

64 Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies

Bernhard Grubmüller, Richard P. Baum, Enza Capasso [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published 2026

Precision Oncology with 177 Lu-PSMA-617 Radionuclide Therapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer

Fayou Zhou, Yongqing Zheng, Liang Huang [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published 2026

Hemoglobin-Based Oxygen Carriers Promoted the Antitumor Effect of 177 Lu-PSMA-617 by Enhancing DNA Repair Capacity of Immune Cells

Danyue Qu, Chenyi Shao, Xinyuan Ji [...]

Cancer Biotherapy and Radiopharmaceuticals

Open accessReview articleFirst published 2023

Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials

Albert Jang, Ayse T. Kendi, Oliver Sartor

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published April, 2021

Examining Absorbed Doses of Indigenously Developed 177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy

Kamaldeep, Gaurav Wanage, Sudeep Kumar Sahu [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published 2026

Validation of Manual In-House Synthesis,Imaging,Biodistribution,and Dosimetry of Tb-161 PSMA-617 for mCRPC Patients in a Tertiary Health Care Center: A Proof-of-Concept Study

Parul Thakral, Nishant Rana, Abhishek Uppal [...]

Cancer Biotherapy and Radiopharmaceuticals

Open accessReview articleFirst published 2022

Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review

Isabel Heidegger, Claudia Kesch, Alexander Kretschmer [...]

Therapeutic Advances in Medical Oncology

Open accessCase reportFirst published 2023

Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review

Duncan E. K. Sutherland, Raghava Kashyap, Price Jackson [...]

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published April, 2025

Intratumoral Distribution of [ 177 Lu]Lu-PSMA-617 Over Time and in Relation to Diagnostic Tracers in Animal Models of Prostate Cancer

Anders Örbom, Joanna Strand, Mohamed Altai [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published October, 2021

Therapeutic Multidose Preparation of a Ready-to-Use 177 Lu-PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy

Avik Chakraborty, Arpit Mitra, Megha Tawate [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published October, 2016

64 Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies

Bernhard Grubmüller, Richard P. Baum, Enza Capasso [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published 2026

Precision Oncology with 177 Lu-PSMA-617 Radionuclide Therapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer

Fayou Zhou, Yongqing Zheng, Liang Huang [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published 2026

Hemoglobin-Based Oxygen Carriers Promoted the Antitumor Effect of 177 Lu-PSMA-617 by Enhancing DNA Repair Capacity of Immune Cells

Danyue Qu, Chenyi Shao, Xinyuan Ji [...]

Cancer Biotherapy and Radiopharmaceuticals

Open accessReview articleFirst published 2023

Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials

Albert Jang, Ayse T. Kendi, Oliver Sartor

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published April, 2021

Examining Absorbed Doses of Indigenously Developed 177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy

Kamaldeep, Gaurav Wanage, Sudeep Kumar Sahu [...]

Cancer Biotherapy and Radiopharmaceuticals